State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Investigations over the past 20 years have demonstrated that antibacterials can vary markedly in the time course of antimicrobial activity. These differences in pharmacodynamic activity have implications for optimal dosage regimens. The results of more recent studies suggest that the magnitude of the pharmacokinetic/pharmacodynamic parameters required for efficacy are relatively similar in animal infection models and in human infections. However, there is still much to learn. Additional studies are needed to further correlate pharmacokinetic/pharmacodynamic parameters for many antibacterials with therapeutic efficacy in a variety of animal infection models and in human infections. The potential value of using pharmacokinetic/pharmacodynamic parameters as guides for establishing optimal dosing regimens for new and old drugs and for new emerging pathogens and resistant organisms, for setting susceptibility breakpoints, and for reducing the cost of drug development should make the continuing search for the therapeutic rationale of antibacterial dosing of mice and men worthwhile.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Moore, R. D., Lietman, P. S., & Smith, C. R. (1987) · Journal of Infectious Diseases · doi:10.1093/infdis/155.1.93 · Cited by 1,139 · cited 1×
“However, the opposite was observed in the major clinical trials correlating pharmacokinetic/pharmacodynamic parameters with the therapeutic efficacy of aminoglycosides [56].”
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham, M. C., & Schentag, J. J. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.5.1073 · Cited by 1,101 · cited 2×
“[52] found that a 24-hour AUC/MIC value of > 125 was associated with satisfactory outcome for seriously ill patients treated with intravenous ciprofloxacin.”
Pallares, R., Liñares, J., Vadillo, M., Cabellos, C., Manresa, F., Viladrich, P. F., Martin, R., & Gudiol, F. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508243330802 · Cited by 773
Correlation of Antimicrobial Pharmacokinetic Parameters with Therapeutic Efficacy in an Animal Model
Vogelman, B., Gudmundsson, S., Leggett, J., Turnidge, J., Ebert, S., & Craig, W. A. (1988) · The Journal of Infectious Diseases · doi:10.1093/infdis/158.4.831 · Cited by 720 · cited 3×
“need to exceed the MIC for 100% of the dosing interval to exert a significant antibacterial effect [25-27, 36].”
Self-citationCraig, W. A. (1995) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/0732-8893(95)00053-d · Cited by 618 · cited 5×
“Several investigators have used multiple dosage regimens in animal infection models to correlate specific pharmacokinetic/pharmacodynamic parameters with the efficacy of various antibacterials against both gram-positive and gram-negative bacilli [9, 25-31].”
InfluentialSelf-citationBlaser, J., Stone, B. B., Groner, M. C., & Zinner, S. H. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.7.1054 · Cited by 481
Pharmacokinetics and pharmacodynamics of antibiotics in otitis media
CRAIG, W. A., & ANDES, D. (1996) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199603000-00015 · Cited by 435 · cited 3×
“pneumoniae and Haemophilus influenzae in patients with otitis media [38, 43].”
InfluentialSelf-citationDrusano, G. L., Johnson, D. E., Rosen, M., & Standiford, H. C. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.3.483 · Cited by 426 · cited 2×
“there is a significant risk of the emergence of resistant subpopulations [29].”
Leggett, J. E., Fantin, B., Ebert, S., Totsuka, K., Vogelman, B., Calame, W., Mattie, H., & Craig, W. A. (1989) · Journal of Infectious Diseases · doi:10.1093/infdis/159.2.281 · Cited by 354
Self-citationKinetics of antimicrobial activity
Vogelman, B., & Craig, W. A. (1986) · The Journal of Pediatrics · doi:10.1016/s0022-3476(86)80754-5 · Cited by 315 · cited 4×
“PAE refers to the persistent suppression of bacterial growth following exposure to an antimicrobial [2, 7, 10].”
InfluentialSelf-citation
Cited by
Items 801–900 of 1,003
Treatment of Legionnaires??? Disease
Amsden, G. W. (2005) · Drugs · doi:10.2165/00003495-200565050-00003 · Cited by 45
Guo, B., Wu, X., Zhang, Y., Shi, Y., Yu, J., Cao, G., & Zhang, J. (2012) · Clinical Drug Investigation · doi:10.2165/11632780-000000000-00000 · Cited by 44
Winter ulcer disease of post-smolt Atlantic salmon: An unsuitable case for treatment?
Coyne, R., Smith, P., Dalsgaard, I., Nilsen, H., Kongshaug, H., Bergh, Ø., & Samuelsen, O. B. (2005) · Aquaculture · doi:10.1016/j.aquaculture.2005.08.016 · Cited by 44
Abdulla, A., Ewoldt, T. M. J., Purmer, I. M., Muller, A. E., Gommers, D. A. M. P. J., Endeman, H., & Koch, B. C. P. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1879049 · Cited by 44
“For β-lactams, the ƒT > MIC value needed for bactericidal activity is between 40% and 70% in in vitro infection models [10,11], this has been confirmed in patients with nosocomial”
BackgroundPotential of Continuous Local Antibiotic Perfusion Therapy for Fracture-Related Infections
Kosugi, K., Zenke, Y., Sato, N., Hamada, D., Ando, K., Okada, Y., Yamanaka, Y., & Sakai, A. (2022) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00653-5 · Cited by 44
Rational use of antibiotics to treat respiratory tract infections.
File, T. M., & Hadley, J. A. (2002) · PubMed · Cited by 44
Farnell, M. B., Donoghue, A. M., Cole, K., Reyes-Herrera, I., Blore, P. J., & Donoghue, D. J. (2005) · Journal of Applied Microbiology · doi:10.1111/j.1365-2672.2005.02712.x · Cited by 44
Pharmacokinetics of doxycycline in sheep after intravenous and oral administration
Robles, L. J. C., Sahagún, A. M., Diez, M. J., Fernández, N., Sierra, M., & Garcia, J. J. (2008) · The Veterinary Journal · doi:10.1016/j.tvjl.2008.02.001 · Cited by 44
“On the other hand, three pharmacokinetic/pharmacodynamic (PK/PD) indices (T > MIC, AUC/MIC and Cmax/ MIC) have been proposed to predict the success or failure of therapy: AUC/MIC ratio for quinolones, Cmax/MIC ratio for aminoglycosides, and T > MIC for b-lactams (Toutain et al., 2002; Toutain and Lees, 2004).”
Once-daily Dosing of Gentamicin in Obstetrics and Gynecology
Ward, K. K., & Theiler, R. N. (2008) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0b013e31818091cd · Cited by 44
“Once-daily dosing also uses the entire duration of the PAE, leaving a long enough dosing interval to avoid bacterial resistance to drug uptake.(3)”
BackgroundShibayama, T., Sugiyama, D., Kamiyama, E., Tokui, T., Hirota, T., & Ikeda, T. (2007) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.22.41 · Cited by 44
Peterson, J. W., Moen, S. T., Healy, D., Peel, J. E., Taormina, J., Hardcastle, J., Thomas, J. M., Lawrence, W. S., Ponce, C., Chatuev, B. M., et al. (2010) · The Open Microbiology Journal · doi:10.2174/1874285801004010034 · Cited by 44
“codynamic data from in vitro, large animal, and human studies suggest that fluoroquinolone efficacy is associated with achieving a maximum serum concentration (Cmax) to minimum inhibitory concentration (MIC) ratio (Cmax/MIC) of >10 and area under the 24-hour serum concentration-time curve to MIC ratio (AUC/MIC) of >12…”
BackgroundErtapenem: A Review of Its Use in the Management of Bacterial Infections
Curran, M. P., Simpson, D., & Perry, C. M. (2003) · Drugs · doi:10.2165/00003495-200363170-00006 · Cited by 44
Palomino, J., & Pachón, J. (2003) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(03)72893-6 · Cited by 44
Matzke, G. R., Frye, R. F., Joy, M. S., & Palevsky, P. M. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.6.1639-1644.2000 · Cited by 44
“concentrations exceed the MIC for the infecting organism (5, 26).”
The application of population pharmacokinetic modeling to individualized antibiotic therapy
Vinks, A. A. T. M. M. (2002) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(02)00023-7 · Cited by 44
Falcó, V., Almirante, B., Jordano, Q., Calonge, L., del Valle, O., Pigrau, C., Planes, A. M., Gavaldà, J., & Pahissa, A. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh338 · Cited by 44
Chung, D. T., Tsai, C., Chen, S., Chang, L.-W., King, C.-H. R., Hsu, C., Chiu, K.-M., Tan, H.-C., Chang, Y., & Hsu, M. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00683-09 · Cited by 43
“Data from a variety of in vitro, animal, and human studies have suggested that the bactericidal activity of FQs is rapid and concentration dependent (10, 20, 26, 27).”
BackgroundAmikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis
Srivastava, S., Modongo, C., Dona, C. W. S., Pasipanodya, J. G., Deshpande, D., & Gumbo, T. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00961-16 · Cited by 43
“In aminoglycoside treatment of Gram-negative bacilli, the peak concentration (Cmax)-to MIC ratio were found to be linked to efficacy, which led to a revolutionary overhaul of aminoglycoside regimens and dramatic improvement in clinical outcomes (6, 7).”
BackgroundModongo, C., Pasipanodya, J. G., Magazi, B. T., Srivastava, S., Zetola, N. M., Williams, S. M., Sirugo, G., & Gumbo, T. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00962-16 · Cited by 43
“Indeed, this is a standard tenet of PK/PD theory (21, 22).”
BackgroundKaushik, A., Ammerman, N. C., Parrish, N. M., & Nuermberger, E. L. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00733-19 · Cited by 43
“Although such targets are not established for β-lactams against MABC 112 organisms, target %fT>MIC values against other bacteria are ≈40% for carbapenems and ≈40113 60% for cephalosporins (19, 20).”
BackgroundAspa, J., Rajas, O., & de Castro, F. R. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.2.229 · Cited by 43
“PD studies show that β -lactam concentrations above the MIC for ∼ 40% of the dosing interval are predictive of bacteriological effi cacy [14] .”
BackgroundScoville, B. A., & Mueller, B. A. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.08.042 · Cited by 43
Xuan, D., Banevicius, M., Capitano, B., Kim, M., Nightingale, C. H., & Nicolau, D. P. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.9.2990-2995.2002 · Cited by 43
“The magnitude of the pharmacokinetic/pharmacodynamic parameter required for a static effect is much less than that observed with penicillin and cephalosporins (2, 3).”
BackgroundJacqueline, C., Broquet, A. H., Roquilly, A., Davieau, M., Caillon, J., Altare, F., Potel, G., & Asehnoune, K. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu145 · Cited by 43
“age of time above the MIC, the major pharmacodynamic index correlating with in vivo efficacy for time-dependent antibiotics [31], we found that linezolid and vancomycin displayed a similar antibacterial activity in infected lung tissues, leading to a 1log10 CFU decrease after 48 hours of treatment.”
BackgroundAntimicrobial Treatment of Ventilator-Associated Pneumonia
Park, D. R. (2005) · Respiratory Care · doi:10.4187/respcare.05500932 · Cited by 43
Pharmacokinetics and pharmacodynamics of antimicrobial drugs
Czock, D., Markert, C., Hartmann, B., & Keller, F. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902913808 · Cited by 43
“The neutropenic mice model is most often used because in immunocompetent mice some microorganisms would not grow at all [25].”
Shea, K. M., Cheatham, S. C., Smith, D. W., Wack, M. F., Sowinski, K. M., & Kays, M. B. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m304 · Cited by 43
Bao, H., Lv, Y., Wang, D., Xue, J., & Yan, Z. (2016) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-016-2819-1 · Cited by 43
“For β-lactam agents, the fraction of the dosing interval during which the free drug concentrations are above the bacterial minimum inhibitory concentration (fT>MIC) is the pharmacodynamic (PD) index that best links drug exposure with the antibacterial effect [8].”
BackgroundBergen, P. J., Bulitta, J. B., Kirkpatrick, C. M. J., Rogers, K. E., McGregor, M. J., Wallis, S. C., Paterson, D. L., Nation, R. L., Lipman, J., Roberts, J. A., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02642-16 · Cited by 43
“(fT>MIC) should be optimized to achieve near-maximal bacterial killing (9, 10).”
BackgroundBonapace, C. R., Friedrich, L. V., Bosso, J. A., & White, R. L. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3574-3579.2002 · Cited by 43
Merchant, S., Gast, C., Nathwani, D., Lee, M., Quintana, A., Ketter, N., Friedland, I. R., & Ingham, M. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.04.001 · Cited by 43
Microbiology and antimicrobial management of sinusitis
Brook, I. (2004) · Otolaryngologic Clinics of North America · doi:10.1016/s0030-6665(03)00155-5 · Cited by 43
“Although standard parameters of antimicrobial activity such as MIC and minimal bactericidal concentration are helpful, they do not provide information about the time course or rate of kill relative to concentration or whether postantibiotic effects contribute to activity [38].”
Home‐based treatment of cellulitis with twice‐daily cefazolin
Leder, K. S., Grayson, M. L., & Turnidge, J. D. (1998) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1998.tb123398.x · Cited by 43
PHARMACODYNAMICS OF ANTIBACTERIAL DRUGS
Levison, M. E. (2000) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(05)70248-8 · Cited by 43
Multiple-dose pharmacokinetics of daptomycin during continuous venovenous haemodiafiltration
Wenisch, J. M., Meyer, B., Fuhrmann, V., Saria, K., Zuba, C., Dittrich, P., & Thalhammer, F. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr551 · Cited by 42
Chiappini, E., Ciarcià, M., Bortone, B., Doria, M., Becherucci, P., Marseglia, G. L., Motisi, M. A., de Martino, M., Galli, L., Licari, A., et al. (2019) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000002429 · Cited by 42
Cao, D., Shen, Y., Huang, Y. C., Chen, B., Chen, Z., Ai, J., Liu, L., Yang, L., & Wei, Q. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.658095 · Cited by 42
“Fluoroquinolones exhibit concentration dependent killing (Craig, 1998) and levofloxacin was characterized by a nearly twice renal excretion rate (84%) than ciprofloxacin (43%), possessed with higher urinary bactericidal titers and long lasting time (Naber, 2001).”
BackgroundNew Antimicrobials, Systemic Distribution, and Local Methods of Antimicrobial Delivery in Horses
Cruz, A. M., Rubio‐Martínez, L. M., & Dowling, T. (2006) · Veterinary Clinics of North America Equine Practice · doi:10.1016/j.cveq.2006.03.006 · Cited by 42
Takata, T., Shimizu, A., Sakakibara, S., Watabe, H., Aizawa, K., & Totsuka, K. (2004) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-003-0292-0 · Cited by 42
Antibiotic Dosing in Slow Extended Daily Dialysis
Mushatt, D. M., Mihm, L. B., Dreisbach, A. W., & Simon, E. E. (2009) · Clinical Infectious Diseases · doi:10.1086/600390 · Cited by 42
“For example, in the case of time-dependent agents, such as b-lactams, the free level of drug needs to be above the MIC for only 40%–50% of the dosing interval to achieve a good outcome [18, 19].”
BackgroundSerum Piperacillin/Tazobactam Pharmacokinetics in a Morbidly Obese Individual
Newman, D., Scheetz, M. H., Adeyemi, O. A., Montevecchi, M., Nicolau, D. P., Noskin, G. A., & Postelnick, M. J. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1k256 · Cited by 42
Antimicrobial activities of some mushrooms in Turkey
Doğan, H. H., Duman, R., Özkalp, B., & Aydın, S. (2013) · Pharmaceutical Biology · doi:10.3109/13880209.2013.764327 · Cited by 42
Rationale for single and high dose treatment regimens with azithromycin
Gordon, E. M., & Blumer, J. L. (2004) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000112523.95762.f5 · Cited by 42
“Clinically it is essential that the unbound or free drug concentration, as opposed to the total drug concentration, exceeds these target values for an adequate period of time.(10) This can be accomplished only with careful consideration of certain key pharmaceutic and pharmacokinetic properties of the drug selected.”
BackgroundAntibiotic Therapy of Methicillin-Resistant Staphylococcus Aureus in Critical Care
Tverdek, F. P., Crank, C. W., & Segreti, J. C. (2008) · Critical Care Clinics · doi:10.1016/j.ccc.2007.12.013 · Cited by 42
Rodríguez-Cerrato, V., McCoig, C. C., Michelow, I. C., Ghaffar, F., Jafri, H. S., Hardy, R. D., Patel, C., Olsen, K. D., & McCracken, G. H. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.11.3092-3097.2001 · Cited by 42
“Like other fluoroquinolones (3), moxifloxacin exhibited concentration-dependent bacterial killing.”
BackgroundNaber, C. K., Hammer, M., Kinzig‐Schippers, M., Sauber, C., Sörgel, F., Bygate, E., Fairless, A. J., Machka, K., & Naber, K. G. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3524-3530.2001 · Cited by 42
“the effectiveness of fluoroquinolones in the treatment of infectious diseases is more dependent on the area under the concentration-time curve (AUC)/MIC and peak/MIC ratios than on the time above the MIC (5).”
BackgroundPenetration of Moxifloxacin into Bone Evaluated by Monte Carlo Simulation
Landersdorfer, C. B., Kinzig, M., Hennig, F. F., Bulitta, J. B., Holzgrabe, U., Drusano, G. L., Sörgel, F., & Gusinde, J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01056-08 · Cited by 42
Acute Bacterial Meningitis beyond the Neonatal Period
Garcia, C. G., & McCracken, G. H. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2702-9.00040-4 · Cited by 42
Cohen, Y., Husain, N., Menan, J., Karayalcin, G., Lehrer, M., & Rubin, L. G. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.5.1565-1567.2001 · Cited by 42
“manner, with the cure of infection correlating with bacterial exposure to an antibiotic concentration greater than the MIC for over 40 to 50% of the time (7).”
BackgroundCredito, K. L., Lin, G., Pankuch, G. A., Bajaksouzian, S., Jacobs, M. R., & Appelbaum, P. C. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.1.67-72.2001 · Cited by 42
“Craig (3) has suggested that breakpoints for azithromycin and clarithromycin against Haemophilus are considerably lower than currently approved values in light of pharmacokinetic and pharmacodynamic parameters (11) and bacteriological outcome studies in otitis media (5, 6).”
BackgroundModeling Oral Multispecies Biofilm Recovery After Antibacterial Treatment
Jing, X., Huang, X., Haapasalo, M., Shen, Y., & Wang, Q. (2019) · Scientific Reports · doi:10.1038/s41598-018-37170-w · Cited by 41
Beta-lactam target attainment and associated outcomes in patients with bloodstream infections
Al‐Shaer, M. H., Maranchick, N. F., Alexander, K. M., Manigaba, K., Shoulders, B. R., Felton, T., Mathew, S. K., & Peloquin, C. A. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.106727 · Cited by 41
Shan, Q., Yang, F., Wang, J., Ding, H., He, L., & Zeng, Z. (2013) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.12076 · Cited by 41
“As time-dependent antibiotics, b-lactam antibiotics have been shown to be most effective when the concentration is maintained above the MIC of the pathogen (Craig, 1998).”
BackgroundZhang, Y.-Q., Xu, J., Yin, Z., Jia, R., Lü, Y., Yang, F., Du, Y.-H., Zou, P., Lv, C., Ting-xiu, H., et al. (2010) · Fitoterapia · doi:10.1016/j.fitote.2010.03.015 · Cited by 41
“However, in recent years, substantial efforts to elucidate the dynamic relationship between pharmacodynamic and pharmacokinetic variables resulted in an in-depth understanding with a logical approach to drug and dosage selection [20].”
BackgroundThe Epidemiologic and Pharmacodynamic Cutoff Values of Tilmicosin against Haemophilus parasuis
Zhang, P., Hao, H., Li, J., Ahmad, I., Cheng, G., Chen, D., Tao, Y., Huang, L., Wang, Y., Dai, M., et al. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00385 · Cited by 41
Bergen, P. J., Bulitta, J. B., Kirkpatrick, C. M. J., Rogers, K. E., McGregor, M. J., Wallis, S. C., Paterson, D. L., Lipman, J., Roberts, J. A., & Landersdorfer, C. B. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw153 · Cited by 41
How preclinical infection models help define antibiotic doses in the clinic
Tängdén, T., Lundberg, C. V., Friberg, L. E., & Huttner, A. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106008 · Cited by 41
“Thus, the neutropenic thigh and lung infection models in mice are most often used [2 , 12] .”
MethodJager, N. G. L., Chai, M. G., van Hest, R. M., Lipman, J., Roberts, J. A., & Cotta, M. O. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.03.041 · Cited by 41
Ng, M., Epstein, S. B., Callahan, M. T., Piotrowski, B. O., Simon, G. L., Roberts, A. D., Keiser, J. F., & Kaplan, J. B. (2013) · Dose-Response · doi:10.2203/dose-response.13-021.kaplan · Cited by 41
“Antibiotic-induced biofilm formation may have clinical relevance because bacteria are exposed to low concentrations of antibiotics during the course of routine antibiotic chemotherapy (Craig, 1998; Odenholt, 2001).”
BackgroundClinical Pharmacokinetics of Quinupristin/Dalfopristin
Bearden, D. T. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443040-00003 · Cited by 41
Delattre, I., Musuamba, F. T., Jacqmin, P., Taccone, F. S., Laterre, P., Verbeeck, R. K., Jacobs, F., & Wallemacq, P. E. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.03.030 · Cited by 41
Curello, J., & MacDougall, C. (2014) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-19.3.156 · Cited by 41
Low, D. E., Pichichero, M. E., & Schaad, U. B. (2004) · Clinical Pediatrics · doi:10.1177/000992280404300203 · Cited by 41
Farzana, K., Shah, S. N. H., & Jabeen, F. (2004) · Journal of Research (Science) · Cited by 41
Pharmacokinetic and Pharmacodynamic Aspects of Antibiotic Use in High-Risk Populations
Bergman, S., Speil, C. A., Short, M., & Koirala, J. (2007) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2007.07.004 · Cited by 41
Moxifloxacin: a review of the microbiological, pharmacological, clinical and safety features
Blondeau, J. M., & Hansen, G. T. (2001) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2.2.317 · Cited by 41
“For example, the maximum serum concentration (Cmax) to MIC ratio should be 8 - 10 [27].”
BackgroundThe Rationale for Aerosolized Antibiotics
Flume, P. A., & Klepser, M. E. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.6.71s.33909 · Cited by 41
“Historically, we have classified antibiotics into two pharmacodynamic categories: those that exhibit concentration-dependent activity and those that exhibit non–concentration-dependent activity.(1) Agents that improve the rate and/or extent of kill as the concentration of drug is increased above the minimum inhibitory…”
Backgroundvan Os, W., & Zeitlinger, M. A. (2021) · Antibiotics · doi:10.3390/antibiotics10121485 · Cited by 40
Housman, S. T., Sutherland, C. A., & Nicolau, D. P. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.05.012 · Cited by 40
Oliver, W. D., Heil, E. L., Gonzales, J. P., Mehrotra, S., Robinett, K. S., Saleeb, P. G., & Nicolau, D. P. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02608-15 · Cited by 40
Huang, C.-C., Tsai, K., Tsai, T., & Hsu, P. (2017) · Biomarker Research · doi:10.1186/s40364-017-0103-x · Cited by 40
“5 regardless of CYP2C19 genotype [46] and maintain steady plasma concentration of amoxicillin above the minimal inhibitory concentration for H pylori [47].”
BackgroundRodvold, K. A., Gotfried, M. H., Chugh, R., Gupta, M., Yeole, R. D., Patel, A. M., & Bhatia, A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02297-17 · Cited by 40
Tøttrup, M., Søballé, K., Bibby, B. M., Hardlei, T. F., Hansen, P., Fuursted, K., Birke‐Sørensen, H., & Bue, M. (2019) · Apmis · doi:10.1111/apm.12996 · Cited by 40
“This means that its efficacy is best related to the time that the free concentration is sustained above the minimal inhibitory concentration of the invading pathogen (MIC) (fT>MIC) (3, 4).”
BackgroundCojutti, P. G., Lazzarotto, D., Candoni, A., Dubbini, M. V., Zannier, M. E., Fanin, R., & Pea, F. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa267 · Cited by 40
Mahmoud, M. E., Fekry, N. A., & Mohamed, S. M. S. (2022) · Journal of Water Process Engineering · doi:10.1016/j.jwpe.2022.102562 · Cited by 40
Marchisio, P., Galli, L., Bortone, B., Ciarcià, M., Motisi, M. A., Novelli, A., Pinto, L., Bottero, S., Pignataro, L., PIACENTINI, G. L., et al. (2019) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000002452 · Cited by 40
“pneumoniae.(52) The division into 2 doses of amoxicillin or amoxicillinclavulanic acid is therefore possible in subjects with a low risk of resistant S.”
BackgroundGonçalves-Pereira, J., Fernandes, J., Duarte, A. R., & Fernandes, S. M. (2022) · Antibiotics · doi:10.3390/antibiotics11121839 · Cited by 40
“Bacteria killing is ensured as soon as this threshold is attained but does not increase significantly with higher concentrations [38].”
BackgroundConil, J., Georges, B., Ruiz, S., Rival, T., Seguin, T., Cougot, P., Fourcade, O., Houin, G., & Saivin, S. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03793.x · Cited by 40
Pharmacokinetics of danofloxacin 18% in lactating sheep and goats
Escudero, E., Cárceles, C. M., Fernández-Varón, E., Marín, P., & Benchaoui, H. A. (2007) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/j.1365-2885.2007.00898.x · Cited by 40
PHARMACOKINETICS AND PHARMACODYNAMICS OF OUTPATIENT INTRAVENOUS ANTIMICROBIAL THERAPY
Andes, D. R., & Craig, W. A. (1998) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(05)70024-6 · Cited by 40
Self-citationBacterial Temporal Dynamics Enable Optimal Design of Antibiotic Treatment
Meredith, H. R., Lopatkin, A. J., Anderson, D. J., & You, L. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004201 · Cited by 40
Ulldemolins, M., Martín‐Loeches, I., Llauradó‐Serra, M., Fernández, J., Vaquer, S., Rodríguez, A. H., Pontes, C., Calvo, G., Torres, A., & Soy, D. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv503 · Cited by 40
What Is Old Is New Again: Delafloxacin, a Modern Fluoroquinolone
Cho, J. C., Crotty, M. P., White, B. P., & Worley, M. V. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2050 · Cited by 40
Schuck, E. L., Dalhoff, A., Stass, H., & Derendorf, H. (2005) · Infection · doi:10.1007/s15010-005-8204-0 · Cited by 40
Batzias, G. C., Delis, G. A., & Athanasiou, L. V. (2004) · The Veterinary Journal · doi:10.1016/j.tvjl.2004.06.007 · Cited by 40
Boy, D., Well, M., Kinzig‐Schippers, M., Sörgel, F., Ankel‐Fuchs, D., & Naber, K. G. (2004) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2003.09.006 · Cited by 40
“According to animal and human studies [5], the efficacy of fluoroquinolones can be considered comparable if peak concentrations and area of concentration time curves above minimal inhibitory/bactericidal activity, which corresponds to the urinary bactericidal titers (UBT), are in the same range.”
BackgroundInfluentialCarbapenems in the USA: focus on doripenem
Lister, P. (2007) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.5.5.793 · Cited by 40
Delivering Antibacterials to the Lungs: Considerations for Optimizing Outcomes
Cazzola, M., Blasi, F., Terzano, C., Matera, M. G., & Marsico, S. A. (2002) · American Journal of Respiratory Medicine · doi:10.1007/bf03256617 · Cited by 40
“[86] The proposed predictive values for T>MIC and bacteriostatic effect in non-neutropenic hosts during intermittent dosing are 20 to 34% of the dosing interval for penicillins, 35 to 55% for cephalosporins and 20 to 26% for carbapenems.”
BackgroundKuti, J. L., Florea, N. R., Nightingale, C. H., & Nicolau, D. P. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.1.8.34804 · Cited by 40
Moczygemba, L. R., Frei, C. R., & Burgess, D. S. (2004) · Clinical Therapeutics · doi:10.1016/j.clinthera.2004.11.009 · Cited by 40
Hershberger, E., & Rybak, M. J. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.598-601.2000 · Cited by 40
“Previous studies have suggested that certain pharmacodynamic parameters may correlate with the therapeutic efficacy of fluoroquinolones (1, 3, 6, 7, 8, 10, 11, 13, 14, 17).”
BackgroundPK/PD-Guided Strategies for Appropriate Antibiotic Use in the Era of Antimicrobial Resistance
Onita, T., Ishihara, N., & Yano, T. (2025) · Antibiotics · doi:10.3390/antibiotics14010092 · Cited by 39
Tøttrup, M., Bue, M., Koch, J., Jensen, L. K., Hanberg, P., Aalbæk, B., Fuursted, K., Jensen, H. E., & Søballé, K. (2016) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.o.00550 · Cited by 39
Moine, P., Mueller, S. W., Schoen, J. A., Rothchild, K. B., & Fish, D. N. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00585-16 · Cited by 39
“The time during which free (unbound) drug concentrations exceed pathogen MICs (fT MIC) is the pharmacokinetic/pharmacodynamic parameter best correlated with bacterial killing and clinical efficacy of -lactam antibiotics (32).”
BackgroundKhan, D. D., Friberg, L. E., & Nielsen, E. I. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw057 · Cited by 39
Rees, V. E., Yadav, R., Rogers, K. E., Bulitta, J. B., Wirth, V., Oliver, A., Boyce, J. D., Peleg, A. Y., Nation, R. L., & Landersdorfer, C. B. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01150-18 · Cited by 39
Venisse, N., Grégoire, N., Marliat, M., & Couet, W. R. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01030-07 · Cited by 39
“The pharmacokinetic-pharmacodynamic (PK-PD) index based on the MIC has been derived in order to accommodate for that difference and has led to the distinction between antimicrobial agents that exhibit time-dependent killing and those that exhibit concentration-dependent killing (8, 27).”
BackgroundMultiple-dose pharmacokinetics of cefepime in long-term hemodialysis with high-flux membranes
Schmaldienst, S., Traunmüller, F., Burgmann, H., Rosenkranz, A. R., Thalhammer-Scherrer, R., Hörl, W. H., & Thalhammer, F. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050721 · Cited by 39
“Maximum killing is seen when T>MIC is at least 60±70% [11].”
BackgroundKuKanich, B. K., Huff, D., Riviere, J. E., & Papich, M. G. (2007) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.230.3.390 · Cited by 39
Penetration of Ertapenem Into Different Pulmonary Compartments of Patients Undergoing Lung Surgery
Burkhardt, O., Majcher-Peszynska, J., Borner, K., Mundkowski, R. G., Drewelow, B., Derendorf, H., & Welte, T. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005276117 · Cited by 39
“In all 12 samples of lung tissue, concentrations exceeded MIC90 values of the respective pathogens within 1.5 to 4.5 hours after the start of infusion (Figure 3).”
BackgroundInfluential
Metadata
- Authors
- Craig, W. A.
- Affiliations
- William S. Middleton Memorial Veterans Hospital (US)
- Corresponding author
- Craig, William A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-01
- Volume
- 26
- Issue
- 1
- Pages
- 1-10
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2113717321
- Cited by
- 2,908
- References
- 50
- Citations by year
- 2026: 68 · 2025: 81 · 2024: 82 · 2023: 99 · 2022: 86 · 2021: 89 · 2020: 103 · 2019: 94 · 2018: 105 · 2017: 124 · 2016: 136 · 2015: 113 · 2014: 129 · 2013: 109 · 2012: 101
- FWCI
- 54.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- pharmacokinetics/pharmacodynamics, dosing regimen, pharmacodynamic parameters, pharmacokinetic parameters, animal models of infection, human infection, susceptibility breakpoints, antimicrobial resistance, emerging pathogens, drug development costs
- MeSH terms
- Animals, Anti-Bacterial Agents, Bacteria, Humans, Lactams, Microbial Sensitivity Tests, Fluoroquinolones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.